{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:37:51Z","timestamp":1792103871612,"version":"4.4.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"CPC Clinical Research"},{"DOI":"10.13039\/100000042","name":"Amgen Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000042","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bristol-Myers Squibb"},{"name":"GlaxoSmithKline"},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021316","name":"AstraZeneca United States","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009109","name":"Pharmaceuticals Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s11886-024-02063-0","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T12:01:51Z","timestamp":1715688111000},"page":"505-520","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Polyvascular Disease: A Narrative Review of Risk Factors, Clinical Outcomes and Treatment"],"prefix":"10.1007","volume":"26","author":[{"given":"Manasi","family":"Tannu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie N.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Antonio","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh V.","family":"Swaminathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Elissa","family":"Altin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil V.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"key":"2063_CR1","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1161\/CIRCRESAHA.121.318535","volume":"128","author":"AW Aday","year":"2021","unstructured":"Aday AW, Matsushita K. Epidemiology of Peripheral Artery Disease and Polyvascular Disease. Circ Res. 2021;128:1818\u201332. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318535.","journal-title":"Circ Res"},{"key":"2063_CR2","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1093\/eurheartj\/ehl114","volume":"27","author":"FGR Fowkes","year":"2006","unstructured":"Fowkes FGR, Low L-P, Tuta S, Kozak J. Ankle-brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: results of the international AGATHA study. Eur Heart J. 2006;27:1861\u20137.","journal-title":"Eur Heart J"},{"key":"2063_CR3","doi-asserted-by":"publisher","first-page":"e007385","DOI":"10.1161\/CIRCINTERVENTIONS.119.007385","volume":"12","author":"JA Gutierrez","year":"2019","unstructured":"Gutierrez JA, Aday AW, Patel MR, Jones WS. Polyvascular Disease: Reappraisal of the Current Clinical Landscape. Circ Cardiovasc Interv. 2019;12:e007385. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.119.007385.","journal-title":"Circ Cardiovasc Interv"},{"key":"2063_CR4","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377:1319\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1709118.","journal-title":"N Engl J Med"},{"key":"2063_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.atherosclerosis.2020.11.001","volume":"315","author":"EH Weissler","year":"2020","unstructured":"Weissler EH, et al. Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy. Atherosclerosis. 2020;315:10\u20137. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.11.001.","journal-title":"Atherosclerosis"},{"key":"2063_CR6","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","volume":"297","author":"PG Steg","year":"2007","unstructured":"Steg PG, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197\u2013206. https:\/\/doi.org\/10.1001\/jama.297.11.1197.","journal-title":"JAMA"},{"key":"2063_CR7","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.286.11.1317","volume":"286","author":"AT Hirsch","year":"2001","unstructured":"Hirsch AT, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317\u201324. https:\/\/doi.org\/10.1001\/jama.286.11.1317.","journal-title":"JAMA"},{"key":"2063_CR8","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/eurheartj\/ehp099","volume":"30","author":"DL Bhatt","year":"2009","unstructured":"Bhatt DL, et al. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J. 2009;30:1195\u2013202. https:\/\/doi.org\/10.1093\/eurheartj\/ehp099.","journal-title":"Eur Heart J"},{"key":"2063_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ijcard.2017.11.081","volume":"254","author":"J-P Collet","year":"2018","unstructured":"Collet J-P, et al. Systematic detection of polyvascular disease combined with aggressive secondary prevention in patients presenting with severe coronary artery disease: The randomized AMERICA Study. Int J Cardiol. 2018;254:36\u201342. https:\/\/doi.org\/10.1016\/j.ijcard.2017.11.081.","journal-title":"Int J Cardiol"},{"key":"2063_CR10","doi-asserted-by":"publisher","first-page":"e185239","DOI":"10.1001\/jamanetworkopen.2018.5239","volume":"1","author":"JA Gutierrez","year":"2018","unstructured":"Gutierrez JA, et al. Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial. JAMA Netw Open. 2018;1:e185239.\u00a0https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.5239.","journal-title":"JAMA Netw Open"},{"key":"2063_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1611688","volume":"376","author":"WR Hiatt","year":"2017","unstructured":"Hiatt WR, et al. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N Engl J Med. 2017;376:32\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1611688.","journal-title":"N Engl J Med"},{"key":"2063_CR12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ejvs.2009.05.006","volume":"38","author":"R Vidakovic","year":"2009","unstructured":"Vidakovic R, et al. The prevalence of polyvascular disease in patients referred for peripheral arterial disease. Eur J Vasc Endovasc Surg. 2009;38:435\u201340. https:\/\/doi.org\/10.1016\/j.ejvs.2009.05.006.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2063_CR13","doi-asserted-by":"publisher","first-page":"A33","DOI":"10.1016\/j.jacc.2006.08.011","volume":"48","author":"P Libby","year":"2006","unstructured":"Libby P, Ridker PM. Inflammation and Atherothrombosis. J Am Coll Cardiol. 2006;48:A33\u201346. https:\/\/doi.org\/10.1016\/j.jacc.2006.08.011.","journal-title":"J Am Coll Cardiol"},{"key":"2063_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1161\/01.ATV.0000105054.43931.f0","volume":"24","author":"PA VanderLaan","year":"2004","unstructured":"VanderLaan PA, Reardon CA, Getz GS. Site specificity of atherosclerosis: site-selective responses to atherosclerotic modulators. Arterioscler Thromb Vasc Biol. 2004;24:12\u201322. https:\/\/doi.org\/10.1161\/01.ATV.0000105054.43931.f0.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2063_CR15","doi-asserted-by":"publisher","first-page":"e017740","DOI":"10.1161\/JAHA.120.017740","volume":"9","author":"O Dikilitas","year":"2020","unstructured":"Dikilitas O, Satterfield BA, Kullo IJ. Risk Factors for Polyvascular Involvement in Patients With Peripheral Artery Disease: A Mendelian Randomization Study. J Am Heart Assoc. 2020;9:e017740.\u00a0https:\/\/doi.org\/10.1161\/JAHA.120.017740.","journal-title":"J Am Heart Assoc"},{"key":"2063_CR16","doi-asserted-by":"publisher","unstructured":"Tian Y, et al. Association of Polyvascular Disease and Elevated Interleukin-6 With Outcomes in Acute Ischemic Stroke or Transient Ischemic Attack. Front Neurol.\u00a02021;12. https:\/\/doi.org\/10.3389\/fneur.2021.661779.","DOI":"10.3389\/fneur.2021.661779"},{"key":"2063_CR17","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1016\/j.atherosclerosis.2007.07.006","volume":"195","author":"SE Elias-Smale","year":"2007","unstructured":"Elias-Smale SE, Kardys I, Oudkerk M, Hofman A, Witteman JC. C-reactive protein is related to extent and progression of coronary and extra-coronary atherosclerosis; results from the Rotterdam study. Atherosclerosis. 2007;195:e195-202. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2007.07.006.","journal-title":"Atherosclerosis"},{"key":"2063_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/crd.0000000000000021","volume":"22","author":"J Hartman","year":"2014","unstructured":"Hartman J, Frishman WH. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev. 2014;22:147\u201351. https:\/\/doi.org\/10.1097\/crd.0000000000000021.","journal-title":"Cardiol Rev"},{"key":"2063_CR19","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.jacc.2019.05.049","volume":"74","author":"N Ding","year":"2019","unstructured":"Ding N, et al. Cigarette Smoking, Smoking Cessation, and Long-Term Risk of 3 Major Atherosclerotic Diseases. J Am Coll Cardiol. 2019;74:498\u2013507. https:\/\/doi.org\/10.1016\/j.jacc.2019.05.049.","journal-title":"J Am Coll Cardiol"},{"key":"2063_CR20","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1161\/CIRCULATIONAHA.108.816181","volume":"119","author":"S Mora","year":"2009","unstructured":"Mora S, et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009;119:931\u20139.","journal-title":"Circulation"},{"key":"2063_CR21","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.107.719369","volume":"117","author":"AD Pradhan","year":"2008","unstructured":"Pradhan AD, et al. Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk. Circulation. 2008;117:823\u201331.","journal-title":"Circulation"},{"key":"2063_CR22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1161\/CIRCGENETICS.111.961292","volume":"5","author":"JM Murabito","year":"2012","unstructured":"Murabito JM, et al. Association between chromosome 9p21 variants and the ankle-brachial index identified by a meta-analysis of 21 genome-wide association studies. Circ Cardiovasc Genet. 2012;5:100\u201312. https:\/\/doi.org\/10.1161\/CIRCGENETICS.111.961292.","journal-title":"Circ Cardiovasc Genet"},{"key":"2063_CR23","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/s41591-019-0492-5","volume":"25","author":"D Klarin","year":"2019","unstructured":"\u2022 Klarin D, et al. Genome-wide association study of peripheral artery disease in the Million Veteran Program. Nat Med. 2019;25:1274\u20139. https:\/\/doi.org\/10.1038\/s41591-019-0492-5. Findings from this genome-wide association study of over 32 million DNA sequence variants in patients with peripheral artery disease found 19 loci associated with peripiheral artery disease and 11 loci associated with disease in coronary, cerebral, and peripheral vascular territories.","journal-title":"Nat Med"},{"key":"2063_CR24","doi-asserted-by":"publisher","first-page":"e2986","DOI":"10.1371\/journal.pone.0002986","volume":"3","author":"P Linsel-Nitschke","year":"2008","unstructured":"Linsel-Nitschke P, et al. Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease\u2013a Mendelian Randomisation study. PLoS ONE. 2008;3:e2986.\u00a0https:\/\/doi.org\/10.1371\/journal.pone.0002986.","journal-title":"PLoS ONE"},{"key":"2063_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2174\/157016110791112304","volume":"8","author":"D Mukherjee","year":"2010","unstructured":"Mukherjee D, Eagle K. The importance of early diagnosis and treatment in peripheral arterial disease: insights from the PARTNERS and REACH registries. Curr Vasc Pharmacol. 2010;8:293\u2013300. https:\/\/doi.org\/10.2174\/157016110791112304.","journal-title":"Curr Vasc Pharmacol"},{"key":"2063_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amjcard.2007.02.046","volume":"100","author":"D Mukherjee","year":"2007","unstructured":"Mukherjee D, et al. Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). Am J Cardiol. 2007;100:1\u20136. https:\/\/doi.org\/10.1016\/j.amjcard.2007.02.046.","journal-title":"Am J Cardiol"},{"key":"2063_CR27","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/eurheartj\/ehp355","volume":"30","author":"MJ Alberts","year":"2009","unstructured":"Alberts MJ, et al. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J. 2009;30:2318\u201326. https:\/\/doi.org\/10.1093\/eurheartj\/ehp355.","journal-title":"Eur Heart J"},{"key":"2063_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2017.04.015","volume":"262","author":"Q Zhang","year":"2017","unstructured":"Zhang Q, et al. Asymptomatic polyvascular disease and the risks of cardiovascular events and all-cause death. Atherosclerosis. 2017;262:1\u20137. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.04.015.","journal-title":"Atherosclerosis"},{"key":"2063_CR29","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1016\/j.jcin.2016.07.034","volume":"9","author":"MP Bonaca","year":"2016","unstructured":"Bonaca MP, et al. Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2 degrees P-TIMI 50 Trial. JACC Cardiovasc Interv. 2016;9:2157\u201364. https:\/\/doi.org\/10.1016\/j.jcin.2016.07.034.","journal-title":"JACC Cardiovasc Interv"},{"key":"2063_CR30","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","volume":"137","author":"MP Bonaca","year":"2018","unstructured":"Bonaca MP, et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018;137:338\u201350. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.032235.","journal-title":"Circulation"},{"key":"2063_CR31","doi-asserted-by":"publisher","first-page":"E2018","DOI":"10.1016\/S0735-1097(13)62018-5","volume":"61","author":"M Bonaca","year":"2013","unstructured":"Bonaca M, et al. Vorapaxar Reduces Peripheral Revascularization Regardless of the number of diseased territories: insights from the Tra2p\u2013Timi 50 trial. J Am Coll Cardiol. 2013;61:E2018\u2013E2018. https:\/\/doi.org\/10.1016\/S0735-1097(13)62018-5.","journal-title":"J Am Coll Cardiol"},{"key":"2063_CR32","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1161\/circoutcomes.111.964379","volume":"5","author":"S Subherwal","year":"2012","unstructured":"Subherwal S, et al. Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2012;5:541\u20139. https:\/\/doi.org\/10.1161\/circoutcomes.111.964379.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2063_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.amjcard.2018.09.014","volume":"123","author":"JA Gutierrez","year":"2019","unstructured":"Gutierrez JA, et al. Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). Am J Cardiol. 2019;123:145\u201352. https:\/\/doi.org\/10.1016\/j.amjcard.2018.09.014.","journal-title":"Am J Cardiol"},{"key":"2063_CR34","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1161\/CIRCULATIONAHA.118.033898","volume":"137","author":"S Verma","year":"2018","unstructured":"Verma S, et al. Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial. Circulation. 2018;137:2179\u201383. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.033898.","journal-title":"Circulation"},{"key":"2063_CR35","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/s2213-8587(18)30290-0","volume":"6","author":"MP Bonaca","year":"2018","unstructured":"Bonaca MP, et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol. 2018;6:934\u201343. https:\/\/doi.org\/10.1016\/s2213-8587(18)30290-0.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2063_CR36","doi-asserted-by":"crossref","unstructured":"Creager MA, L\u00fcscher TF, prepare with the assistance of, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation.\u00a02003;108:1527\u20131532.","DOI":"10.1161\/01.CIR.0000091257.27563.32"},{"key":"2063_CR37","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1161\/01.CIR.0000089189.70578.E2","volume":"108","author":"TF Luscher","year":"2003","unstructured":"Luscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. Circulation. 2003;108:1655\u201361.","journal-title":"Circulation"},{"key":"2063_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2021.10.011","volume":"338","author":"MD Samsky","year":"2021","unstructured":"Samsky MD, et al. Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial. Atherosclerosis. 2021;338:1\u20136. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.10.011.","journal-title":"Atherosclerosis"},{"key":"2063_CR39","doi-asserted-by":"publisher","first-page":"e15959","DOI":"10.1097\/md.0000000000015959","volume":"98","author":"K Fujisue","year":"2019","unstructured":"Fujisue K, et al. Prognostic significance of polyvascular disease in heart failure with preserved left ventricular ejection fraction. Medicine (Baltimore). 2019;98:e15959. https:\/\/doi.org\/10.1097\/md.0000000000015959.","journal-title":"Medicine (Baltimore)"},{"key":"2063_CR40","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ijcard.2021.07.008","volume":"339","author":"WJ Jang","year":"2021","unstructured":"Jang WJ, et al. Association between polyvascular disease and clinical outcomes in patients with cardiogenic shock: Results from the RESCUE registry. Int J Cardiol. 2021;339:70\u20134. https:\/\/doi.org\/10.1016\/j.ijcard.2021.07.008.","journal-title":"Int J Cardiol"},{"key":"2063_CR41","doi-asserted-by":"publisher","first-page":"e726","DOI":"10.1161\/CIR.0000000000000471","volume":"135","author":"MD Gerhard-Herman","year":"2017","unstructured":"Gerhard-Herman MD, et al. 2016 AHA\/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e726\u201379. https:\/\/doi.org\/10.1161\/CIR.0000000000000471.","journal-title":"Circulation"},{"key":"2063_CR42","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"V Aboyans","year":"2018","unstructured":"Aboyans V, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763\u2013816. https:\/\/doi.org\/10.1093\/eurheartj\/ehx095.","journal-title":"Eur Heart J"},{"key":"2063_CR43","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/cir.0000000000001168","volume":"148","author":"SS Virani","year":"2023","unstructured":"Virani SS, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148:e9\u2013119. https:\/\/doi.org\/10.1161\/cir.0000000000001168.","journal-title":"Circulation"},{"key":"2063_CR44","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/s0140-6736(96)09457-3","volume":"348","author":"CS Committee","year":"1996","unstructured":"Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee Lancet. 1996;348:1329\u201339. https:\/\/doi.org\/10.1016\/s0140-6736(96)09457-3.","journal-title":"CAPRIE Steering Committee Lancet"},{"key":"2063_CR45","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","volume":"67","author":"MP Bonaca","year":"2016","unstructured":"Bonaca MP, et al. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2016;67:2719\u201328. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.524.","journal-title":"J Am Coll Cardiol"},{"key":"2063_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1109719","volume":"366","author":"P Tricoci","year":"2011","unstructured":"Tricoci P, et al. Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. N Engl J Med. 2011;366:20\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1109719.","journal-title":"N Engl J Med"},{"key":"2063_CR47","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1161\/strokeaha.111.000433","volume":"44","author":"DA Morrow","year":"2013","unstructured":"Morrow DA, et al. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke. 2013;44:691\u20138. https:\/\/doi.org\/10.1161\/strokeaha.111.000433.","journal-title":"Stroke"},{"key":"2063_CR48","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41569-019-0314-y","volume":"17","author":"D Capodanno","year":"2020","unstructured":"Capodanno D, et al. Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nat Rev Cardiol. 2020;17:242\u201357. https:\/\/doi.org\/10.1038\/s41569-019-0314-y.","journal-title":"Nat Rev Cardiol"},{"key":"2063_CR49","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jacc.2021.04.083","volume":"78","author":"JW Eikelboom","year":"2021","unstructured":"Eikelboom JW, et al. Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. J Am Coll Cardiol. 2021;78:14\u201323. https:\/\/doi.org\/10.1016\/j.jacc.2021.04.083.","journal-title":"J Am Coll Cardiol"},{"key":"2063_CR50","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/s0140-6736(17)32409-1","volume":"391","author":"SS Anand","year":"2018","unstructured":"Anand SS, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet. 2018;391:219\u201329. https:\/\/doi.org\/10.1016\/s0140-6736(17)32409-1.","journal-title":"The Lancet"},{"key":"2063_CR51","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1001\/jamacardio.2020.4390","volume":"6","author":"E Kaplovitch","year":"2021","unstructured":"Kaplovitch E, et al. Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial. JAMA Cardiology. 2021;6:21\u20139. https:\/\/doi.org\/10.1001\/jamacardio.2020.4390.","journal-title":"JAMA Cardiology"},{"key":"2063_CR52","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","volume":"382","author":"MP Bonaca","year":"2020","unstructured":"Bonaca MP, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020;382:1994\u20132004. https:\/\/doi.org\/10.1056\/NEJMoa2000052.","journal-title":"N Engl J Med"},{"key":"2063_CR53","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1136\/heartjnl-2014-306906","volume":"101","author":"RM Stoekenbroek","year":"2015","unstructured":"Stoekenbroek RM, et al. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. Heart. 2015;101:356\u201362. https:\/\/doi.org\/10.1136\/heartjnl-2014-306906.","journal-title":"Heart"},{"key":"2063_CR54","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"key":"2063_CR55","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082\u2013143. https:\/\/doi.org\/10.1161\/CIR.0000000000000625.","journal-title":"Circulation"},{"key":"2063_CR56","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1161\/str.0000000000000375","volume":"52","author":"DO Kleindorfer","year":"2021","unstructured":"Kleindorfer DO, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association\/American Stroke Association. Stroke. 2021;52:e364\u2013467. https:\/\/doi.org\/10.1161\/str.0000000000000375.","journal-title":"Stroke"},{"key":"2063_CR57","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","volume":"80","author":"DM Lloyd-Jones","year":"2022","unstructured":"Lloyd-Jones DM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80:1366\u2013418. https:\/\/doi.org\/10.1016\/j.jacc.2022.07.006.","journal-title":"J Am Coll Cardiol"},{"key":"2063_CR58","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.jacc.2019.03.013","volume":"74","author":"JW Jukema","year":"2019","unstructured":"\u2022 Jukema JW, et al. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019;74:1167\u201376. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.013. This trial demonstrated that treatment with the PCSK9 inhibitor alirocumb led to a reduction in major adverse cardiac events (comprising of cardiovascular death, myocardial infarction, ischemic stroke, and unstable angina requiring hospitalization) with greater absolute risk reductions observed with each additional vascular territory involved.","journal-title":"J Am Coll Cardiol"},{"key":"2063_CR59","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.atherosclerosis.2011.08.024","volume":"219","author":"K Hibi","year":"2011","unstructured":"Hibi K, et al. Clinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound from the Japanese assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) trial. Atherosclerosis. 2011;219:743\u20139. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.08.024.","journal-title":"Atherosclerosis"},{"key":"2063_CR60","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376:1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"key":"2063_CR61","doi-asserted-by":"publisher","first-page":"e017948","DOI":"10.1161\/jaha.120.017948","volume":"10","author":"M Alkhalil","year":"2021","unstructured":"Alkhalil M, Kuzemczak M, Whitehead N, Kavvouras C, D\u017eav\u00edk V. Meta-Analysis of Intensive Lipid-Lowering Therapy in Patients With Polyvascular Disease. J Am Heart Assoc. 2021;10:e017948.\u00a0https:\/\/doi.org\/10.1161\/jaha.120.017948.","journal-title":"J Am Heart Assoc"},{"key":"2063_CR62","doi-asserted-by":"publisher","unstructured":"Wiviott S, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.\u00a0N Engl J Med.\u00a02019;380. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","DOI":"10.1056\/NEJMoa1812389"},{"key":"2063_CR63","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/s0140-6736(18)32261-x","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519\u201329. https:\/\/doi.org\/10.1016\/s0140-6736(18)32261-x.","journal-title":"Lancet"},{"key":"2063_CR64","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","volume":"3","author":"G Rakipovski","year":"2018","unstructured":"Rakipovski G, et al. The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE(-\/-) and LDLr(-\/-) Mice by a Mechanism That Includes Inflammatory Pathways. JACC Basic Transl Sci. 2018;3:844\u201357. https:\/\/doi.org\/10.1016\/j.jacbts.2018.09.004.","journal-title":"JACC Basic Transl Sci"},{"key":"2063_CR65","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377:1119\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1707914.","journal-title":"N Engl J Med"},{"key":"2063_CR66","unstructured":"US National Library of Medicine. ClinicalTrials.gov. 2023.\u00a0https:\/\/clinicaltrials.gov\/study\/NCT05021835."},{"key":"2063_CR67","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/ng.3396","volume":"47","author":"M Nikpay","year":"2015","unstructured":"Nikpay M, et al. A comprehensive 1000 Genomes\u2013based genome-wide association meta-analysis of coronary artery disease. Nat Genet. 2015;47:1121\u201330. https:\/\/doi.org\/10.1038\/ng.3396.","journal-title":"Nat Genet"},{"key":"2063_CR68","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ana.21191","volume":"62","author":"I Sibon","year":"2007","unstructured":"Sibon I, et al. COL4A1 mutation in Axenfeld-Rieger anomaly with leukoencephalopathy and stroke. Ann Neurol. 2007;62:177\u201384. https:\/\/doi.org\/10.1002\/ana.21191.","journal-title":"Ann Neurol"},{"key":"2063_CR69","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41588-018-0058-3","volume":"50","author":"R Malik","year":"2018","unstructured":"Malik R, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat Genet. 2018;50:524\u201337. https:\/\/doi.org\/10.1038\/s41588-018-0058-3.","journal-title":"Nat Genet"},{"key":"2063_CR70","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jacc.2020.05.048","volume":"76","author":"LD Colantonio","year":"2020","unstructured":"Colantonio LD, et al. Atherosclerotic Risk and Statin Use Among Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2020;76:251\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2020.05.048.","journal-title":"J Am Coll Cardiol"},{"key":"2063_CR71","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jvs.2017.10.044","volume":"67","author":"EL Chaikof","year":"2018","unstructured":"Chaikof EL, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. J Vasc Surg. 2018;67:2-77.e72. https:\/\/doi.org\/10.1016\/j.jvs.2017.10.044.","journal-title":"J Vasc Surg"},{"key":"2063_CR72","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1307684.","journal-title":"N Engl J Med"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-024-02063-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-024-02063-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-024-02063-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T06:26:24Z","timestamp":1719296784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-024-02063-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2063"],"URL":"https:\/\/doi.org\/10.1007\/s11886-024-02063-0","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]},"assertion":[{"value":"18 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Rao reports no relationships with industry. Dr Tannu reports no conflicts. Dr. Hess reports receiving salary support from CPC Clinical Research; a member of the Executive Committee for EVOLVE-MI; and a grant from Amgen to CPC Clinical Research to fund the EVOLVE-MI trial. Dr. Lopes reports grants from Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, Pfizer, and Sanofi; consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, and Novo Nordisk; payment or honoraria from AstraZeneca, Daiichi Sankyo, Novo Nordisk, and Pfizer. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}